Categories
Change Password!
Reset Password!
A randomized controlled trial aimed to examine the masticatory dysfunction following low- LTP-RFA and RFT ablation on trigeminal ganglion for idiopathic trigeminal neuralgia treatment.
Base on the hypothesis that low-temperature plasma
radiofrequency ablation (LTP-RFA) is non-inferior to radiofrequency
thermocoagulation (RFT) with concerning initial efficacy, this study proved
LTP-RFA had noninferior efficacy for pain relief and supporting healthy
masticatory function.
A randomized
controlled trial aimed to examine the masticatory dysfunction following low-
LTP-RFA and RFT ablation on trigeminal ganglion for idiopathic trigeminal
neuralgia treatment.
In this single-blind, parallel-group, noninferiority trial, 204 patients with idiopathic trigeminal neuralgia were divided into: LTP-RFA group where plasma ablation was used and RFT group where radiofrequency ablation was used, with random block sizes of 4 or 6.
Examination was done at starting (T0), on day of
discharge (T1) and at 6 months (T2). Clinical effective
rate in the LTP-RFA group compared to RFT group following the intervention on
T1 was the primary endpoint.
LTP-RFA group had initial efficacy rate of 91.2% and RFT group had 93.1% as per the intention-to-treat analysis. Difference between these two groups displayed that LTP-RFA was non inferiority than RFT in initial efficacy.
The LTP-RFA group showed a considerably greater improvement
in the highest voltage of masseter with T1 and T2 having mean
differences of 11.40 and 17.41 as compared to RFT group. Activity index of anterior
temporalis and masseter, asymmetry index for occlusal force, highest voltage of anterior
temporalis had comparable results.
LTP-RFA group but not RFT group portrayed noninferior
efficacy for pain relief and recovery of healthy masticatory function.
Pain Medicine
Masticatory Dysfunction After Computed Tomography–Guided Plasma Ablation vs. Radiofrequency Ablation on Gasserian Ganglion for Idiopathic Trigeminal Neuralgia: A Randomized Controlled Trial
Shuyue Zheng et al.
Comments (0)